Clincosm LogoSign in Get a demo

moderate to severe plaque psoriasis

Showing 1 - 25 of 27
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Moderate to Severe Plaque Psoriasis Trial in China (ICP-488 Tablets, ICP-488 Placebo)

Not yet recruiting
  • Moderate to Severe Plaque Psoriasis
  • ICP-488 Tablets
  • ICP-488 Placebo
  • Bengbu, Anhui, China
  • +31 more
Oct 26, 2023

Moderate to Severe Plaque Psoriasis Trial in El Salvador, United States (Placebo, SCD-044_Dose 1, SCD-044_Dose 2)

Recruiting
  • Moderate to Severe Plaque Psoriasis
  • Placebo
  • +3 more
  • Yuma, Arizona
  • +19 more
Aug 26, 2022

Moderate to Severe Plaque Psoriasis Trial in Worldwide (bimekizumab)

Active, not recruiting
  • Moderate to Severe Plaque Psoriasis
  • Indianapolis, Indiana
  • +10 more
Aug 19, 2022

Moderate to Severe Plaque Psoriasis Trial in Korea, Republic of (bimekizumab, Placebo)

Active, not recruiting
  • Moderate to Severe Plaque Psoriasis
  • Bucheon-si, Korea, Republic of
  • +8 more
Jul 28, 2022

Moderate to Severe Plaque Psoriasis Trial in Canada, United States (NDI-034858 study drug, Placebo)

Active, not recruiting
  • Moderate to Severe Plaque Psoriasis
  • NDI-034858 study drug
  • Placebo
  • Birmingham, Alabama
  • +68 more
Jun 16, 2022

Moderate to Severe Plaque Psoriasis Trial in Saint Petersburg (BCD-085 Q2W, BCD-085 Q4W, Placebo)

Completed
Has Results
  • Moderate to Severe Plaque Psoriasis
  • BCD-085 Q2W
  • +2 more
  • Saint Petersburg, Strelna, Russian Federation
    BIOCAD
May 11, 2022

Moderate to Severe Plaque Psoriasis Trial (TLL018 tablets)

Not yet recruiting
  • Moderate to Severe Plaque Psoriasis
  • TLL018 tablets
  • (no location specified)
Apr 22, 2022

Psoriasis, Moderate to Severe Plaque Psoriasis Trial in Worldwide (Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab

Active, not recruiting
  • Psoriasis
  • Moderate to Severe Plaque Psoriasis
  • Stelara® (Ustekinumab)
  • SB17 (Proposed Ustekinumab Biosimilar)
  • Brno, Czechia
  • +32 more
Apr 13, 2022

Moderate to Severe Plaque Psoriasis Trial in Gyeonggi-do, Pusan, Seoul (CT303)

Recruiting
  • Moderate to Severe Plaque Psoriasis
  • CT303
  • Gyeonggi-do, Korea, Republic of
  • +2 more
Mar 3, 2022

Moderate to Severe Plaque Psoriasis Trial in China (KHK4827-Active, KHK4827-Placebo)

Withdrawn
  • Moderate to Severe Plaque Psoriasis
  • Changchun, China
  • +24 more
Sep 24, 2021

Moderate to Severe Plaque Psoriasis Trial in United States (Midazolam, AIN457)

Completed
  • Moderate to Severe Plaque Psoriasis
  • Birmingham, Alabama
  • +7 more
Dec 9, 2020

Humira in Psoriasis Patients in Routine Clinical Practice

Completed
  • Moderate to Severe Plaque Psoriasis
    • Heidelberg, Baden-Wuerttemberg, Germany
    • +640 more
    Jun 11, 2020

    Moderate to Severe Plaque Psoriasis Trial in Jinshan (608, Placebo)

    Unknown status
    • Moderate to Severe Plaque Psoriasis
    • Jinshan, Shanghai, China
      Public Health Clinical Center (Shanghai)
    Apr 25, 2020

    Provide Real-world Evidence on Treatment Goal Achievement Rate,

    Completed
    • Moderate to Severe Plaque Psoriasis
      • Athens, Attiki, Greece
      • +42 more
      Apr 14, 2020

      Moderate to Severe Plaque Psoriasis Trial in Worldwide (210 mg brodalumab, 140 mg brodalumab, ustekinumab)

      Terminated
      Has Results
      • Moderate to Severe Plaque Psoriasis
      • 210 mg brodalumab
      • +3 more
      • Birmingham, Alabama
      • +153 more
      Jan 3, 2020

      Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis Trial in Worldwide (MSB11022, Humira®)

      Completed
      Has Results
      • Psoriasis
      • +2 more
      • San Luis Obispo, California
      • +75 more
      Dec 13, 2019

      Moderate to Severe Plaque Psoriasis Trial in Lübeck (Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet)

      Withdrawn
      • Moderate to Severe Plaque Psoriasis
      • Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
      • Lübeck, Germany
        Comprehensive Center for Inflammation Medicine, UKSH
      Apr 16, 2019

      Moderate to Severe Plaque Psoriasis Trial in Seoul (KHK4827, Placebo)

      Completed
      • Moderate to Severe Plaque Psoriasis
      • Seoul, Korea, Republic of
        Korea, Republic of
      Sep 9, 2018

      Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis Trial in United States (IMO-3100 at 0.16 mg/kg, Saline

      Completed
      Has Results
      • Actively Extending Plaque Psoriasis
      • Moderate to Severe Plaque Psoriasis
      • IMO-3100 at 0.16 mg/kg
      • +2 more
      • Jacksonville, Florida
      • +12 more
      Dec 12, 2017

      Adalimumab in Moderate to Severe Plaque Psoriasis Distinct

      Completed
      Has Results
      • Moderate to Severe Plaque Psoriasis
        • (no location specified)
        May 12, 2017

        Patient-Reported Experiences of Living With Moderate-to-Severe

        Completed
        • Moderate to Severe Plaque Psoriasis
        • No intervention
        • Phoenix, Arizona
        • +8 more
        Jul 20, 2015

        Moderate to Severe Plaque Psoriasis Trial in Russian Federation (Adalimumab)

        Completed
        Has Results
        • Moderate to Severe Plaque Psoriasis
        • Adalimumab
        • Ekaterinburg, Russian Federation
        • +6 more
        Sep 22, 2014

        Adalimumab in Treatment of Scalp and Nail Affection in Moderate

        Completed
        Has Results
        • Moderate to Severe Plaque Psoriasis
          • Chotoviny, Czech Republic
          • +72 more
          Jul 15, 2014

          Moderate to Severe Plaque Psoriasis Trial in Chiyoda-ku (KHK4827, Placebo)

          Completed
          • Moderate to Severe Plaque Psoriasis
          • Chiyoda-ku, Tokyo, Japan
            For additional information regarding investigative sites for thi
          Sep 3, 2013

          Moderate to Severe Plaque Psoriasis Trial in Worldwide (ABT-874)

          Completed
          • Moderate to Severe Plaque Psoriasis
          • Birmingham, Alabama
          • +151 more
          Jan 28, 2013